Serum total gangliosides and TA90-IC levels: Novel immunologic markers in colorectal cancer

Cancer Journal

Volumn 8, Issue 1, 2002, Pages 55-61

  Perez, Carlos A ^a   Ravindranath, Mepur H ^a   Gupta, Rishab K ^a   Tollenaar, Rob A E M ^b   Van De Velde, Cornelius J ^b   Wood, Thomas F ^a   Soh, Daniel ^a   Morton, Donald L ^a   Bilchik, Anton J ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GANGLIOSIDE; GLYCOPROTEIN; GLYOPROTEIN TA90 IMMUNE COMPLEX; LIPID; MONOCLONAL ANTIBODY; SIALIC ACID; UNCLASSIFIED DRUG; TA90 IMMUNE COMPLEX; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HUMAN; LIPID BLOOD LEVEL; LYMPH NODE; MALE; METASTASIS; MINIMAL RESIDUAL DISEASE; OPTICAL DENSITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; BLOOD; COLON TUMOR; IMMUNOLOGY; MIDDLE AGED; RECTUM TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GANGLIOSIDES; HUMANS; MALE; MIDDLE AGED; RECTAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0036364462     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200201000-00010     Document Type: Article

References (27)

1. American Cancer Society, Surveillance Research, 2001. Vital statistics of the United States, 2000.
2. Parker SL, Tong T, Bolden S et al. Cancer statistics, 1997. CA Cancer J Clin 1197;47:5-27.
3. American Joint Committee on Cancer. AJCC Cancer Staging Manual, 5th ed. Philadelphia: Lippincott-Raven, 1997.
4. Hermanek P. pTNM and residual tumor classifications: problems of assessment and prognostic significance. World J Surg 1995;19:184-190.
5. Bengtsson G, Carlsson G, Hafstrom L et al. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1991;141:586-589.
6. Adson MA, van Heerden JA, Adson MH et al. Resection of hepatic metastasis from colon cancer. Arch Surg 1984;119:647-651.
7. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914.
8. Kemeny N, Huang Y, Cohen AM et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039-2048.
9. Thompson JA, Grunert F, Zimmerman W et al. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991;5:344-366.
10. Carpelan-Holmstrom MA, Haglund CH, Roberts PJ. Differences in serum tumor markers between colon and rectal cancer. Dis Colon Rectum 1996;39:799-805.
11. Von Kleist S, Hesse Y, Kananeeh H. Comparative evaluation of four tumor markers, CA242, CA19/9, TPA and CEA in carcinomas of the colon. Anticancer Res 1996;16:2325-2332.
12. Carpelan-Holmstrom MA, Haglund C, Javinen HJ et al. Serum CA242 and CEA detect different patients with recurrent colorectal cancer. Anticancer Res 1996;16:981-986.
13. Moertel CG, Fleming TR, MacDonald JS et al. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993;270:943-947.
14. Ferroni P, Lenti L, Guadagni F et al. Possible involvement of tumour cell membrane gangliosides in platelet-tumour cell interactions. Eur J Cancer 1995;31A:79-84.
15. Nishinaka Y, Ravindranath MH, Irie RF. Development of a human monoclonal antibody to ganglioside GM2 with potential for cancer treatment. Cancer Res 1996;56:5666-5671.
16. Chu KU, Ravindranath MH, Gonzales AM et al. Gangliosides as targets for immunotherapy for pancreatic adenocarcinoma. Cancer 2000;88:1828-1836.
17. Hsueh EC, Nathanson L, Foshag LJ et al. Active specific immunotherapy with polyvalent melanoma cell vaccine in patients with in-transit melanoma metastases. Cancer 1999;85:2160-2169.
18. Gupta RK. Circulating immune complexes in malignant melanoma. Dis Markers 1988;6:81-96.
19. Gupta RK, Morton DL. Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated antigen-specific immune complexes in cancer patients. J Clin Lab Anal 1992;6:329-336.
20. Euhus DM, Gupta RK, Morton DL. Characterization of a 90-100kDa tumor-associated antigen in the sera of melanoma patients. Int J Cancer 1990;45:1065-1070.
21. Kelley MC, Jones RC, Gupta RK et al. Tumor-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early stage melanoma. Cancer 1998;83:1355-1361.
22. Kelley MC, Gupta RK, Hsueh EC et al. Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma. J Clin Oncol 2001;19:1176-1182.
23. Hsueh EC, Gupta RK, Qi K et al. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma. Cancer J Sci Am 1997;3:364-370.
24. Habal N, Gupta RK, Bilchik AJ et al. TA90-IC, a new marker for advanced colon cancer. Ann Surg Oncol 2000;7:352-356.
25. Katopodis N, Hirschaut Y, Geller NL et al. Lipid-associated sialic acid test for the detection of human cancer. Cancer Res 1982;42:5270-5275.
26. Harrison LE, Guillem JG, Paty P et al. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg 1997;185:55-59.
27. Schulz G, Cheresh DA, Varki NM et al. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 1984;44:5914-5920.